Abstract 1393P
Background
Patients with driver-gene mutations in NSCLC can benefit significantly from corresponding targeted therapy, but respond poorly to immunotherapy (such as EGFR, ALK). As a driver-gene of NSCLC, the relationship between the characteristics of MET and many immune indicators in the Chinese population is still unclear. This study aims to elucidate the characteristics of the MET gene and its relationship with immune indicators in the Chinese NSCLC population.
Methods
732 Formalin-Fixed Paraffin-Embedded (FFPE) lung adenocarcinoma samples were collected and detected by Next Generation Sequencing 603-gene panel from July, 2021 to March, 2023 were selected from the study. The biomarkers of immunotherapy (TMB-High [≥10/Mb], and MMR-related genes (MLH1, MSH2, MSH6, PMS2) were also calculated.
Results
Among the 732 subjects included in the previous detection, a total of 32 cases were detected to carry MET-related mutations. The detection rate of MET gene was 4.37%. The median age was 65 (13-97). 15% of patients belonged to exon 14 skipping type (5/32); MET amplification accounted for the least, accounting for only 6% (2/32 ). The top 3 of mutation frequency were Met_L221W (4/32), MET_Q1067K (2/32), and MET_F206S (2/32). The gene partners of Met co-mutation were analyzed, and the top five genes were PPP2R1A, HIST1H3G, CDKN1B, SYK, and ERBB4. In the analysis of the immune indicators of the MET mutant population and wild-type population, the Mann-Whitney U test found that among the TMB indicators, the mean value of the MET group was 8.09 with SD of 7.91, and the mean value of the un-MET group was 5.94 with SD of 4.98. MET was correlated with TMB with statistical difference (P value 0.02).We also paid attention to MET and MMR-related genes. The analysis showed that there was a significant relationship between MET group and wild-type MET group and MMR gene (p-value: 0.026).
Conclusions
In the Chinese NSCLC population, there is a correlation between MET expression and TMB, and the MET mutation will increase the TMB value. MET expression was significantly correlated with MMR-related gene mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1412P - SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors
Presenter: Alessandra Curioni-Fontecedro
Session: Poster session 20
1414P - Impact of co-mutations on the prognosis of targeted therapy in EGFR-mutant advanced NSCLC: A result of real-world study
Presenter: Sisi Pan
Session: Poster session 20
1416P - Recurrence of infusion-related reaction (IRRs) associated to avimantamab
Presenter: Maria Virginia Sanchez Becerra
Session: Poster session 20
1417P - Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2019: An observational study from the French national claims database
Presenter: Christos Chouaid
Session: Poster session 20
1418P - Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study
Presenter: Rupesh Kotecha
Session: Poster session 20
1419P - TACSTD2 (Trop-2) constitutes a promising antibody-drug conjugate target for patients with non-small cell lung cancer brain metastases
Presenter: Sara Hijazo-Pechero
Session: Poster session 20
1420P - Real-life management of octogenarians with NSCLC in a French nationwide cohort
Presenter: Romain Corre
Session: Poster session 20
1421P - AI-powered intracranial tumor response predicts systemic progression with high concordance in endpoint evaluation in the phase III CROWN study
Presenter: Shao-Lun Lu
Session: Poster session 20
1422P - Comprehensive genomic profiling (CGP) changes management and improves survival in patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: George Simon
Session: Poster session 20